Gene Logic Collaboration Reveals Genomic Predictors of Parkinson's Disease
June 18 2007 - 11:15AM
Business Wire
Gene Logic Inc. (NASDAQ:GLGC) announced today that a collaborative
study between its Genomics Division and Mayo Clinic has found
biomarkers that predict susceptibility to Parkinson�s disease and
age of disease onset. The study was novel in its detailed and
comprehensive analysis of genes and their polymorphic variants
across a specific biologic pathway. This work may also provide a
model for the study of other complex diseases such as Alzheimer�s.
Parkinson�s disease is a chronic and progressive movement disorder
that affects nearly one million Americans. The collaborators used
sophisticated bioinformatic analysis methods to compare gene
sequence variations called single nucleotide polymorphisms (SNPs)
in the genomes of Parkinson�s disease patients to those of their
disease-free siblings. The collaborators targeted variants of genes
related to the axon guidance pathway, a neural development pathway
that plays an important role in the wiring of the brain during
fetal development. Gene Logic provided gene expression data
analysis and data interpretation, comparing the whole-genome study
data to the company�s Parkinson�s disease gene expression
knowledgebase, referred to in the study as the most comprehensive
such database to date. Jarlath ffrench-Mullen, Ph.D., Gene Logic
Scientific Director, Central Nervous System, and a co-author of the
study said, �The study methodology opens doors to more in-depth
genetic understanding of complex diseases, demonstrating the value
of our clinical and genomics assets and capabilities. Gene
expression profiles are used in such studies to identify,
understand and confirm the dysregulation of specific genes and gene
variants in a target pathway. This study augments our intellectual
property position around a growing set of useful markers for
Parkinson�s disease and other complex diseases, affording excellent
opportunities to develop diagnostic, prognostic, or therapeutic
products.� Gene Logic Overview Gene Logic is transforming into a
biopharmaceutical development company through partnerships with
pharmaceutical companies. Our partners provide Gene Logic with
access to their drug candidates that have been assessed as safe in
human clinical trials but discontinued for other reasons. Gene
Logic applies its drug indication platform to find new therapeutic
uses for the drug candidates. Gene Logic expects to receive
milestone payments and royalties on drug candidates that our
partners choose to develop based on the indications we find or, if
the partner elects not to pursue such new indications, Gene Logic
may receive ownership and development rights. Gene Logic has also
developed proprietary genomics databases and services to enable
customers worldwide to discover and prioritize drug targets,
identify biomarkers, predict toxicity and understand mechanisms of
toxicity, and obtain insights into the efficacy of specific
compounds. Founded in 1994, Gene Logic is headquartered in
Gaithersburg, Maryland, with additional research and development
facilities in Cambridge, Massachusetts. The Company currently has
about 150 employees worldwide. For more information, visit
www.genelogic.com or call toll-free � 1/800/GENELOGIC. Safe Harbor
Statement This press release contains �forward-looking statements,�
as such term is used in the Securities Exchange Act of 1934, as
amended. Such forward-looking statements include the Company�s
ability to identify strategies for making its businesses successful
and the impact of such strategies on our business and financial
performance and on shareholder value. Forward-looking statements
typically include the words �expect,� �anticipate,� �believe,�
�estimate,� �intend,� �may,� �will,� and similar expressions as
they relate to Gene Logic or its management. Forward-looking
statements are based on our current expectations and assumptions,
which are subject to risks and uncertainties. They are not
guarantees of our future performance or results. Our actual
performance and results could differ materially from what we
project in forward-looking statements for a variety of reasons and
circumstances, including particularly such risks and uncertainties
that may affect the Company�s operations, financial condition and
financial results and that are discussed in detail in the Company�s
Annual Report on Form 10-K and our other subsequent filings with
the Securities and Exchange Commission. They include, but are not
limited to: whether we will be able to identify and successfully
implement strategies, on favorable terms or at all, for improving
the performance and value of our businesses and improving the value
of our Genomics business and whether repositioned compounds are
successfully returned to our customers� pipelines and generate
sales, and resulting milestones and royalties for the Company or
whether we acquire repositioned compounds on acceptable terms and
are able to derive revenue from these compounds through licensing
or otherwise, whether we can enter into agreements to develop
sufficient compounds to fulfill our plans for the Drug
Repositioning Division, and improving the value of our businesses
to shareholders; whether there will be remaining price adjustments
or liabilities associated with the sale of the Pre-Clinical
Division, whether we will be able successfully to manage our
existing cash adequately and whether we will have access to
financing on sufficiently favorable terms to maintain our
businesses and effect our strategies, including development of
repositioned compounds; whether we will be able to recruit and
retain qualified personnel, particularly in light of our
restructuring efforts; potential negative effects on our operations
and financial results from workforce reductions, other
restructuring activities, and the evaluation of strategic options;
the potential loss of significant customers; the possibility of
further write-down of the value of certain intangible assets of the
Company, including goodwill associated with the Genomics Division;
and the possibility of delisting from NASDAQ Global Markets, which
could have an adverse effect on the value of our stock. Gene Logic
undertakes no obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Gene Logic Inc. (MM) (NASDAQ:GLGC)
Historical Stock Chart
From Jul 2024 to Aug 2024
Gene Logic Inc. (MM) (NASDAQ:GLGC)
Historical Stock Chart
From Aug 2023 to Aug 2024